Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis

Presse Medicale

Volumn 44, Issue 6, 2015, Pages e251-e257

  Flossmann, Oliver ^a  

^a ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; IMMUNOSUPPRESSIVE AGENT;

ANCA ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASE; CHURG STRAUSS SYNDROME; DEMOGRAPHY; DRUG EFFICACY; GENETIC SUSCEPTIBILITY; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPIC POLYANGIITIS; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PROGNOSIS; QUALITY OF LIFE; RELAPSE; RISK ASSESSMENT; SCAR FORMATION; SHORT SURVEY; SURVIVAL RATE; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE PREDISPOSITION; FOLLOW UP; IMMUNOCOMPROMISED PATIENT; IMMUNOCOMPROMIZED PATIENT; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDY (TOPIC); NEOPLASMS; OPPORTUNISTIC INFECTIONS; PULMONARY FIBROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK; TREATMENT OUTCOME;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CARDIOVASCULAR DISEASES; DISEASE SUSCEPTIBILITY; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; OPPORTUNISTIC INFECTIONS; PROGNOSIS; PULMONARY FIBROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK; TREATMENT OUTCOME;

EID: 84930872131     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2015.02.019     Document Type: Short Survey

References (49)

1. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013, 65:1-11.
2. Jayne D. L27. Antibodies versus phenotypes: a clinician's view. Presse Med 2013, 42:579-582.
3. Mukhtyar C., Flossmann O., Hellmich B., Bacon P., Cid M., Cohen-Tervaert J.W., et al. Outcomes from studies of antineutrophil cytoplasm antibody-associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008, 67:1004-1010.
4. Holle J.U., Gross W.L., Latza U., Nolle B., Ambrosch P., Heller M., et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011, 63:257-266.
5. Hilhorst M., Wilde B., van Paassen P., Winkens B., van Breda Vriesman P., Cohen-Tervaert J.W. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 2013, 28:373-379.
6. Flossmann O., Berden A., de Groot K., Hagen C., Harper L., Heijl C., et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011, 70:488-494.
7. Guillevin L., Lhote F., Gayraud M., Cohen P., Jarrousse B., Lortholary O., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
8. Samson M., Puechal X., Devilliers H., Ribi C., Cohen P., Bienvenu B., et al. Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor prognosis factors. Autoimmun Rev 2014, 13:197-205.
9. Luqmani R., Suppiah R., Edwards C.J., Phillip R., Maskell J., Culliford D., et al. Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology (Oxford) 2011, 50:697-702.
10. Samson M., Puechal X., Devilliers H., Ribi C., Cohen P., Stern M., et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 2013, 43:60-69.
11. Comarmond C., Pagnoux C., Khellaf M., Cordier J.F., Hamidou M., Viallard J.F., et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term follow-up of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013, 65:270-281.
12. Mohammad A.J., Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 2014, 41:1366-1373.
13. Walsh M., Casian A., Flossmann O., Westman K., Hoglund P., Pusey C., et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013, 84:397-402.
14. de Joode A.A., Sanders J.S., Stegeman C.A. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol 2013, 8:1709-1717.
15. Bomback A.S., Appel G.B., Radhakrishnan J., Shirazian S., Herlitz L.C., Stokes B., et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int 2011, 79:757-764.
16. Berden A.E., Ferrario F., Hagen E.C., Jayne D.R., Jennette J.C., Joh K., et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010, 21:1628-1636.
17. Hilhorst M., Wilde B., van Breda Vriesman P., van Paassen P., Cohen-Tervaert J.W. Estimating renal survival using the ANCA-associated GN classification. J Am Soc Nephrol 2013, 24:1371-1375.
18. Chang D.Y., Wu L.H., Liu G., Chen M., Kallenberg C.G., Zhao M.H. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant 2012, 27:2343-2349.
19. Marco H., Mirapeix E., Arcos E., Comas J., Ara J., Gil-Vernet S., et al. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant 2013, 27:338-347.
20. Geetha D., Eirin A., True K., Valentina Irazabal M., Specks U., Seo P., et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. Transplantation 2011, 91:1370-1375.
21. Tang W., Bose B., McDonald S.P., Hawley C.M., Badve S.V., Boudville N., et al. The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand. Clin J Am Soc Nephrol 2013, 8:773-780.
22. Romeu M., Couchoud C., Delaroziere J.C., Burtey S., Chiche L., Harle J.R., et al. Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011. QJM 2014, 107:545-555.
23. Comarmond C., Crestani B., Tazi A., Hervier B., Adam-Marchand S., Nunes H., et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014, 93:340-349.
24. Lai Q.Y., Ma T.T., Li Z.Y., Chang D.Y., Zhao M.H., Chen M. Predictors for mortality in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a study of 398 Chinese patients. J Rheumatol 2014, 41:1849-1855.
25. Little M.A., Nightingale P., Verburgh C.A., Hauser T., De Groot K., Savage C., et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010, 69:1036-1043.
26. Walsh M., Flossmann O., Berden A., Westman K., Hoglund P., Stegeman C., et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:542-548.
27. Pagnoux C., Hogan S.L., Chin H., Jennette J.C., Falk R.J., Guillevin L., et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008, 58:2908-2918.
28. Pierrot-Deseilligny Despujol C., Pouchot J., Pagnoux C., Coste J., Guillevin L. Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 2010, 49:2181-2190.
29. Faurschou M., Westman K., Rasmussen N., de Groot K., Flossmann O., Hoglund P., et al. Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:3472-3477.
30. Harper L., Morgan M.D., Walsh M., Hoglund P., Westman K., Flossmann O., et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012, 71:955-960.
31. Walsh M., Faurschou M., Berden A., Flossmann O., Bajema I., Hoglund P., et al. Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2014, 9:1571-1576.
32. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
33. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
34. Faurschou M., Sorensen I.J., Mellemkjaer L., Loft A.G., Thomsen B.S., Tvede N., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008, 35:100-105.
35. Faurschou M., Mellemkjaer L., Voss A., Keller K.K., Hansen I.T., Baslund B. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford) 2014, [pii: keu372]. 10.1093/rheumatology/keu372.
36. Heijl C., Harper L., Flossmann O., Stucker I., Scott D.G., Watts R.A., et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis 2011, 70:1415-1421.
37. Faurschou M., Mellemkjaer L., Sorensen I.J., Svalgaard Thomsen B., Dreyer L., Baslund B. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009, 60:1187-1192.
38. Faurschou M., Obel N., Baslund B. High risk of pulmonary embolism and deep venous thrombosis but not of stroke in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2014, 66:1910-1914.
39. Suppiah R., Judge A., Batra R., Flossmann O., Harper L., Hoglund P., et al. A model to predict cardiovascular events in patients with newly diagnosed wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011, 63:588-596.
40. Flossmann O., Harper L., Heijl C., Höglund P., Jayne D., Luqmani R., et al. Outcome of ANCA-associated vasculitis - long-term follow-up of four randomised controlled trials. J Am Soc Nephrol 2007, 18:819.
41. Goupil R., Brachemi S., Nadeau-Fredette A.C., Deziel C., Troyanov Y., Lavergne V., et al. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013, 8:416-423.
42. Jones R.B., Tervaert J.W., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010, 363:211-220.
43. Guillevin L., Pagnoux C., Karras A., Khouatra C., Aumaitre O., Cohen P., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014, 371:1771-1780.
44. Robson J., Doll H., Suppiah R., Flossmann O., Harper L., Hoglund P., et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials. Ann Rheum Dis 2015, 74:177-184.
45. Robson J., Doll H., Suppiah R., Flossmann O., Harper L., Hoglund P., et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2014, 54:471-481.
46. Tomasson G., Boers M., Walsh M., Lavalley M., Cuthbertson D., Carette S., et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care Res (Hoboken) 2012, 64:273-279.
47. Faurschou M., Sigaard L., Bjorner J.B., Baslund B. Impaired health-related quality of life in patients treated for Wegener's granulomatosis. J Rheumatol 2010, 37:2081-2085.
48. Basu N., McClean A., Harper L., Amft E.N., Dhaun N., Luqmani R.A., et al. The characterisation and determinants of quality of life in ANCA-associated vasculitis. Ann Rheum Dis 2014, 73:207-211.
49. Basu N., McClean A., Harper L., Amft E.N., Dhaun N., Luqmani R.A., et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (Oxford) 2014, 53:953-956.